Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 9/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 10/20 | 0.56 |
| ▸ | RAB9A | P51151 | 9/20 | 0.56 |
| ▸ | NPC1 | O15118 | 8/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | CASP3 | P42574 | 1/20 | 0.48 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.48 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.48 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10192133 | 0.89 | NPC1 (0.57) | HPGDSMN1; SMN2RAB9ANPC1CYP1A2 | |
| SCHEMBL10192206 | 0.87 | NPC1 (0.51) | HPGDSMN1; SMN2RAB9ANPC1CYP1A2 | |
| SCHEMBL1026416 | 0.81 | LMNA (0.61) | HPGDSMN1; SMN2RAB9ANPC1CYP1A2 | |
| SCHEMBL7562459 | 0.81 | SMN1; SMN2 (0.77) | HPGDSMN1; SMN2RAB9ANPC1CYP1A2 | |
| SCHEMBL19938056 | 0.80 | SMN1; SMN2 (0.67) | HPGDSMN1; SMN2RAB9ANPC1ALDH1A1 | |
| SCHEMBL1274778 | 0.78 | HPGD (0.63) | HPGDSMN1; SMN2RAB9ANPC1CYP1A2 | |
| SCHEMBL7564873 | 0.78 | HPGD (0.79) | HPGDSMN1; SMN2RAB9ANPC1CYP1A2 | |
| SCHEMBL7562461 | 0.78 | SMN1; SMN2 (0.69) | HPGDSMN1; SMN2RAB9ANPC1CYP1A2 | |
| SCHEMBL10192026 | 0.78 | SMN1; SMN2 (0.69) | HPGDSMN1; SMN2RAB9ANPC1CYP1A2 | |
| SCHEMBL19938054 | 0.78 | HPGD (0.69) | HPGDSMN1; SMN2RAB9ANPC1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| US-7973069-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100292187-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | OAT, HAVCR2, HCCS | HPGD 1033/4885SMN1; SMN2 4525/4885RAB9A 3975/4885 |
| US-20100292187-A1 | METHODS FOR TREATING HEPATITIS C | HAVCR2, EIF2AK2, MAVS | HPGD 3255/4885SMN1; SMN2 3609/4885RAB9A 2829/4885 |
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | HAVCR2, EIF2AK2, MAVS | HPGD 3255/4885SMN1; SMN2 3609/4885RAB9A 2829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.